Filing search / Agios Pharmaceuticals, Inc. / "Strategy"

S-8

EX-5.1

AGIO Agios Pharmaceuticals, Inc.

5 Mar 25

Registration of securities for employees

5:27pm

commencement of employment with the Company as the Chief Corporate Development & Strategy Officer pursuant to Nasdaq Stock Market Rule 5635(c)(4

S-8

AGIO Agios Pharmaceuticals, Inc.

5 Mar 25

Registration of securities for employees

5:27pm

to Krishnan Viswanadhan, the registrant’s Chief Corporate Development & Strategy Officer, on March 5, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4 … an inducement restricted stock unit award granted to Mr. Viswanadhan, the registrant’s Chief Corporate Development & Strategy Officer, on March 5, 2025

8-K

EX-99.1

AGIO Agios Pharmaceuticals, Inc.

13 Feb 25

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

6:32am

,” “strategy,” “will,” “vision,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements … public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research

8-K

EX-99.2

AGIO Agios Pharmaceuticals, Inc.

13 Jan 25

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

7:01am

. The words “anticipate”, “expect”, “goal”, “hope”, “milestone”, “opportunity”, “plan”, “potential”, “possible”, “strategy”, “will”, “vision … of pandemics or other public health emergencies to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned

8-K

EX-99.1

1qjizmbtnbwph1sd

13 Jan 25

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

7:01am

8-K

EX-99.1

u46pb x3sx3y

31 Oct 24

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

6:56am

8-K

EX-99.1

nx49n

1 Aug 24

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

7:03am

8-K

EX-99.1

sxdmm2cvp0i1s1w

28 May 24

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

7:09am

8-K

EX-99.1

tojgbq6j2hq3

2 May 24

Agios Reports Business Highlights and First Quarter 2024 Financial Results

7:01am

8-K

EX-99.1

3jyghb

15 Feb 24

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

7:03am

8-K

EX-99.1

bywqli jt67uv4gxk

8 Jan 24

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

7:58am

8-K

EX-99.2

1a47pmsq5

8 Jan 24

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

7:58am

8-K

EX-99.1

m568md5p kn21e79t

2 Nov 23

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

7:02am